Bellicum Pharmaceuticals, INC: insider trades · United States · SEC (Form 4)

About Bellicum Pharmaceuticals, INC

Bellicum Pharmaceuticals, Inc. (ticker BLCM) is a U.S.-based biopharmaceutical company historically listed on NASDAQ in the United States. Founded in 2004 and long headquartered in Houston, Texas, near the Texas Medical Center, the company was built around controllable cell-therapy technologies and proprietary cell-signaling platforms. Its original investment case centered on next-generation immunotherapies for cancer and selected blood-disorder indications, with an emphasis on combining anti-tumor efficacy with built-in safety control. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1358403/000156459015001868/blcm-10k_20141231.htm?utm_source=openai)) From a business-line perspective, Bellicum’s historical pipeline was organized around several proprietary platforms, notably CaspaCIDe® (a drug-activated safety switch), iMC (inducible MyD88/CD40), and the GoCAR-T® platform. These technologies were designed to improve expansion, persistence, and anti-tumor activity of engineered cells while giving physicians an added control mechanism if adverse events emerged. The best-known programs included BPX-501, aimed at complications associated with allogeneic hematopoietic stem cell transplantation, and BPX-601 and BPX-603, developed for oncology, particularly solid tumors. ([ir.bellicum.com](https://ir.bellicum.com/news-releases/news-release-details/bellicum-closes-20-million-series-b-financing?utm_source=openai)) In competitive terms, Bellicum operated in the highly crowded cell-therapy and immuno-oncology arena, where large pharma groups, well-funded specialty biotechs, and academic spinouts compete for clinical differentiation, intellectual property, and capital. Bellicum’s core differentiator was its controllability layer—an appealing scientific thesis, but one that typically requires long development timelines, substantial funding, and rigorous clinical execution. The company also relied on collaborations and licensing arrangements to advance its technology base, including partnerships with major cancer centers and academic institutions. ([ir.bellicum.com](https://ir.bellicum.com/news-releases/news-release-details/bellicum-reports-third-quarter-2021-financial-results-and?utm_source=openai)) Recent corporate developments are critical. In March 2023, Bellicum announced it was discontinuing its Phase 1/2 GoCAR-T trials and initiating a review of strategic alternatives. In November 2023, the company entered into an asset purchase agreement with The University of Texas MD Anderson Cancer Center covering substantially all of its R&D assets; that asset sale was completed on February 21, 2024. In 2023, the company also disclosed that its shares were expected to move to OTCQX, underscoring a major contraction in the listed equity story. For investors, Bellicum should therefore be viewed less as a conventional growth-stage biotech and more as a restructuring/asset-monetization situation. ([ir.bellicum.com](https://ir.bellicum.com/news-releases/news-release-details/bellicum-discontinues-phase-12-trials-and-initiates-evaluation?utm_source=openai))